1) In China, it is the first time to adopt glucocorticoid pulse (methylprednisolone pulse, MP-pulse) therapy to treat systemic lupus erythematosus / juvenile dermatomyositis / polyarteritis and other diseases. Especially for refractory cases, most of the curative effects are satisfactory and the side effects are mininal, which is obviously better than the current mainstream traditional treatment.

2) In China, it is the first time to carry out the treatment of interleukin-2 (IL-2) in children with lupus erythematosus and other immune diseases to reduce hormone dependence.

3) It carried out the individualized treatment of juvenile idiopathic arthritis by using biological agents.

4) The department imported the fully automatic UNI-CAP in vitro allergen detection system (ImmunoCAP system, Phadia 250), built an allergy and immunization laboratory, and carried out standardized full quantitative allergen detection.